- Home
- BMRC vs ALT Comparison
BMRC vs ALT Comparison
Compare BMRC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMRC | ALT |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.8M | 421.5M |
| IPO Year | 2007 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BMRC | ALT |
|---|---|---|
| Price | $29.03 | $2.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $28.67 | $17.67 |
| AVG Volume (30 Days) | 156.7K | ★ 3.3M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $391.81 | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | $57.17 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $21.77 | $2.56 |
| 52 Week High | $30.92 | $6.44 |
Technical Indicators
Market Signals| Indicator | BMRC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 54.11 |
| Support Level | $25.25 | $2.87 |
| Resistance Level | $29.93 | $3.09 |
| Average True Range (ATR) | 0.82 | 0.16 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 39.63 | 41.07 |
Price Performance
Historical ComparisonAbout BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.